Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Verifying a smart pillbox and a accompanied B2B business model in a clinical setting

Reference number
Coordinator PILLOXA AB
Funding from Vinnova SEK 544 500
Project duration May 2018 - June 2019
Status Completed

Important results from the project

The purpose and objective of the project has been twofold: (1) Testing the response of Pilloxa in patients with epilepsy (2) Verify whether Pilloxa can be sold to pharmaceutical companies through a B2B model. Fulfilment: Through the project we have been able to get feedback on how people with epilepsy experience using Pilloxa and to verify that Pilloxa can be sold to pharmaceutical companies.

Expected long term effects

Some patients appreciated Pilloxa very much, some patients with poorer cognitive ability did not appreciate Pilloxa to the same extent. The healthcare staff still see Pilloxa as a tool that would really be needed for this patient population. In parallel, we were able to verify that the B2B business model could be scaled up with pharmaceutical companies.

Approach and implementation

All preliminary work for the study was carried out in accordance with. plan. The inclusion of patients in AP2 was slower than expected, as fewer people with sufficient cognition could be identified by the clinic. In the evaluation of AP3, it was clear that Pilloxa works well for patients with normal cognition but worse for patients with lower cognition than average.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2018-01805

Page statistics